Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4

NCT01381094 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT01381094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01381094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2011
Completion date
February 16, 2012
Enrollment
93 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, kidney disease